Cargando…

Assessing tobacco smoke exposure in pregnancy from self-report, urinary cotinine and NNAL: a validation study using the New Hampshire Birth Cohort Study

OBJECTIVES: Accurate assessment of tobacco smoke exposure is key to evaluate its effects. We sought to validate and establish cut-offs for self-reported smoking and secondhand smoke (SHS) exposure during pregnancy using urinary cotinine and 4-(methylnitrosamino)-1-(-3-pyridyl)-1-butanol (NNAL) in a...

Descripción completa

Detalles Bibliográficos
Autores principales: Peacock, Janet L, Palys, Thomas J, Halchenko, Yuliya, Sayarath, Vicki, Takigawa, Cindy A, Murphy, Sharon E, Peterson, Lisa A, Baker, Emily R, Karagas, Margaret R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8823089/
https://www.ncbi.nlm.nih.gov/pubmed/35131829
http://dx.doi.org/10.1136/bmjopen-2021-054535
_version_ 1784646736646504448
author Peacock, Janet L
Palys, Thomas J
Halchenko, Yuliya
Sayarath, Vicki
Takigawa, Cindy A
Murphy, Sharon E
Peterson, Lisa A
Baker, Emily R
Karagas, Margaret R
author_facet Peacock, Janet L
Palys, Thomas J
Halchenko, Yuliya
Sayarath, Vicki
Takigawa, Cindy A
Murphy, Sharon E
Peterson, Lisa A
Baker, Emily R
Karagas, Margaret R
author_sort Peacock, Janet L
collection PubMed
description OBJECTIVES: Accurate assessment of tobacco smoke exposure is key to evaluate its effects. We sought to validate and establish cut-offs for self-reported smoking and secondhand smoke (SHS) exposure during pregnancy using urinary cotinine and 4-(methylnitrosamino)-1-(-3-pyridyl)-1-butanol (NNAL) in a large contemporary prospective study from the USA, with lower smoking prevalence than has previously been evaluated. DESIGN: Prospective birth cohort. SETTING: Pregnancy clinics in New Hampshire and Vermont, USA. PARTICIPANTS: 1396 women enrolled in the New Hampshire Birth Cohort Study with self-reported smoking, urinary cotinine, NNAL and pregnancy outcomes. PRIMARY AND SECONDARY OUTCOME MEASURES: Cut-offs for urinary cotinine and NNAL concentrations were estimated from logistic regression models using Youden’s method to predict SHS and active smoking. Cotinine and NNAL were each used as the exposure in separate multifactorial models for pregnancy outcomes. RESULTS: Self-reported maternal smoking was: 72% non-smokers, 5.7% ex-smokers, 6.4% SHS exposure, 6.2% currently smoked, 10% unreported. Cotinine and NNAL levels were low and highly intercorrelated (r=0.91). Geometric mean cotinine, NNAL were 0.99 ng/mL, 0.05 pmol/mL, respectively. Cotinine cut-offs for SHS, current smoking were 1.2 ng/mL and 1.8 ng/mL (area under curve (AUC) 95% CI: 0.52 (0.47 to 0.57), 0.90 (0.85 to 0.94)). NNAL cut-off for current smoking was 0.09 pmol/mL (AUC=0.82 (95% CI 0.77 to 0.87)). Using cotinine and NNAL cut-offs combined gave similar AUC to cotinine alone, 0.87 (95% CI 0.82 to 0.91). Cotinine and NNAL gave almost identical effect estimates when modelling pregnancy outcomes. CONCLUSIONS: In this population, we observed high concordance between self-complete questionnaire smoking data and urinary cotinine and NNAL. With respect to biomarkers, either cotinine or NNAL can be used as a measure of tobacco smoke exposure overall but only cotinine can be used to detect SHS.
format Online
Article
Text
id pubmed-8823089
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-88230892022-02-17 Assessing tobacco smoke exposure in pregnancy from self-report, urinary cotinine and NNAL: a validation study using the New Hampshire Birth Cohort Study Peacock, Janet L Palys, Thomas J Halchenko, Yuliya Sayarath, Vicki Takigawa, Cindy A Murphy, Sharon E Peterson, Lisa A Baker, Emily R Karagas, Margaret R BMJ Open Epidemiology OBJECTIVES: Accurate assessment of tobacco smoke exposure is key to evaluate its effects. We sought to validate and establish cut-offs for self-reported smoking and secondhand smoke (SHS) exposure during pregnancy using urinary cotinine and 4-(methylnitrosamino)-1-(-3-pyridyl)-1-butanol (NNAL) in a large contemporary prospective study from the USA, with lower smoking prevalence than has previously been evaluated. DESIGN: Prospective birth cohort. SETTING: Pregnancy clinics in New Hampshire and Vermont, USA. PARTICIPANTS: 1396 women enrolled in the New Hampshire Birth Cohort Study with self-reported smoking, urinary cotinine, NNAL and pregnancy outcomes. PRIMARY AND SECONDARY OUTCOME MEASURES: Cut-offs for urinary cotinine and NNAL concentrations were estimated from logistic regression models using Youden’s method to predict SHS and active smoking. Cotinine and NNAL were each used as the exposure in separate multifactorial models for pregnancy outcomes. RESULTS: Self-reported maternal smoking was: 72% non-smokers, 5.7% ex-smokers, 6.4% SHS exposure, 6.2% currently smoked, 10% unreported. Cotinine and NNAL levels were low and highly intercorrelated (r=0.91). Geometric mean cotinine, NNAL were 0.99 ng/mL, 0.05 pmol/mL, respectively. Cotinine cut-offs for SHS, current smoking were 1.2 ng/mL and 1.8 ng/mL (area under curve (AUC) 95% CI: 0.52 (0.47 to 0.57), 0.90 (0.85 to 0.94)). NNAL cut-off for current smoking was 0.09 pmol/mL (AUC=0.82 (95% CI 0.77 to 0.87)). Using cotinine and NNAL cut-offs combined gave similar AUC to cotinine alone, 0.87 (95% CI 0.82 to 0.91). Cotinine and NNAL gave almost identical effect estimates when modelling pregnancy outcomes. CONCLUSIONS: In this population, we observed high concordance between self-complete questionnaire smoking data and urinary cotinine and NNAL. With respect to biomarkers, either cotinine or NNAL can be used as a measure of tobacco smoke exposure overall but only cotinine can be used to detect SHS. BMJ Publishing Group 2022-02-07 /pmc/articles/PMC8823089/ /pubmed/35131829 http://dx.doi.org/10.1136/bmjopen-2021-054535 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Epidemiology
Peacock, Janet L
Palys, Thomas J
Halchenko, Yuliya
Sayarath, Vicki
Takigawa, Cindy A
Murphy, Sharon E
Peterson, Lisa A
Baker, Emily R
Karagas, Margaret R
Assessing tobacco smoke exposure in pregnancy from self-report, urinary cotinine and NNAL: a validation study using the New Hampshire Birth Cohort Study
title Assessing tobacco smoke exposure in pregnancy from self-report, urinary cotinine and NNAL: a validation study using the New Hampshire Birth Cohort Study
title_full Assessing tobacco smoke exposure in pregnancy from self-report, urinary cotinine and NNAL: a validation study using the New Hampshire Birth Cohort Study
title_fullStr Assessing tobacco smoke exposure in pregnancy from self-report, urinary cotinine and NNAL: a validation study using the New Hampshire Birth Cohort Study
title_full_unstemmed Assessing tobacco smoke exposure in pregnancy from self-report, urinary cotinine and NNAL: a validation study using the New Hampshire Birth Cohort Study
title_short Assessing tobacco smoke exposure in pregnancy from self-report, urinary cotinine and NNAL: a validation study using the New Hampshire Birth Cohort Study
title_sort assessing tobacco smoke exposure in pregnancy from self-report, urinary cotinine and nnal: a validation study using the new hampshire birth cohort study
topic Epidemiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8823089/
https://www.ncbi.nlm.nih.gov/pubmed/35131829
http://dx.doi.org/10.1136/bmjopen-2021-054535
work_keys_str_mv AT peacockjanetl assessingtobaccosmokeexposureinpregnancyfromselfreporturinarycotinineandnnalavalidationstudyusingthenewhampshirebirthcohortstudy
AT palysthomasj assessingtobaccosmokeexposureinpregnancyfromselfreporturinarycotinineandnnalavalidationstudyusingthenewhampshirebirthcohortstudy
AT halchenkoyuliya assessingtobaccosmokeexposureinpregnancyfromselfreporturinarycotinineandnnalavalidationstudyusingthenewhampshirebirthcohortstudy
AT sayarathvicki assessingtobaccosmokeexposureinpregnancyfromselfreporturinarycotinineandnnalavalidationstudyusingthenewhampshirebirthcohortstudy
AT takigawacindya assessingtobaccosmokeexposureinpregnancyfromselfreporturinarycotinineandnnalavalidationstudyusingthenewhampshirebirthcohortstudy
AT murphysharone assessingtobaccosmokeexposureinpregnancyfromselfreporturinarycotinineandnnalavalidationstudyusingthenewhampshirebirthcohortstudy
AT petersonlisaa assessingtobaccosmokeexposureinpregnancyfromselfreporturinarycotinineandnnalavalidationstudyusingthenewhampshirebirthcohortstudy
AT bakeremilyr assessingtobaccosmokeexposureinpregnancyfromselfreporturinarycotinineandnnalavalidationstudyusingthenewhampshirebirthcohortstudy
AT karagasmargaretr assessingtobaccosmokeexposureinpregnancyfromselfreporturinarycotinineandnnalavalidationstudyusingthenewhampshirebirthcohortstudy